Abbott Rides High After Torcetrapib Collapse: Is Everything Old New Again?

The end of torcetrapib was bad news for Pfizer, and could be a death knell for the entire CETP inhibitor class. But it also makes Abbott's acquisition of Kos look prescient. Wall Street is taking notice.